Ucb SA 2018 IR
The report outlines UCB's Patient Value Strategy and its transition to the 'Accelerate & Expand' phase (2019-2021). Key highlights include reaching a milestone of over 3.3 million patients using UCB's core medicines, such as Cimzia, Vimpat, and Briviact. Financially, UCB achieved a 2% revenue growth to ’4.6 billion and a recurring EBITDA of ’1.4 billion. On the environmental front, the company made progress toward its 2030 targets, reducing carbon emissions by 30% compared to the 2015 baseline and aiming for carbon neutrality.
Company: Ucb SA
Sector: Manufacturing
Country: Belgium
Year: 2018
Type: IR
Pages: 288
Back to company
Ucb SA
Integrated Annual Report
The report outlines UCB's Patient Value Strategy and its transition to the 'Accelerate & Expand' phase (2019-2021). Key highlights include reaching a milestone of over 3.3 million patients using UCB's core medicines, such as Cimzia, Vimpat, and Briviact. Financially, UCB achieved a 2% revenue growth to ’4.6 billion and a recurring EBITDA of ’1.4 billion. On the environmental front, the company made progress toward its 2030 targets, reducing carbon emissions by 30% compared to the 2015 baseline and aiming for carbon neutrality.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees